Promising Gout Drug Fails FDA Approval Process - MedPage Today

Visit Bulgaria

Promising Gout Drug Fails FDA Approval Process MedPage Today WASHINGTON -- The FDA rejected pegloticase (Krystexxa) as a treatment for chronic gout, according to ... Gout treatment fails to win approvalBoston Globe Savient Gout Drug Needs Added Info; Stock PlungesWall Street Journal Savient Pharma (SVNT) Lower On FDA Refusal of Gout Treatment, But ...StreetInsider.com (subscription) TheStreet.com -MedPage Today -Wall Street Journal all 72 news articles »

Mark Steyn: Unplugging Grandma isn't the problem - OCRegister

Mark Steyn: Unplugging Grandma isn't the problem OCRegister So, in two hours in New Hampshire, she got tested and diagnosed (with gout) and prescribed something to deal with it. It's the difference between health ...

PicksThatMove: www.PicksThatMove.com: "Picks that move" Alerts ... - Trading Markets (press release) (press release)

PicksThatMove: www.PicksThatMove.com: "Picks that move" Alerts ... Trading Markets (press release) (press release) RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. ... and more »

Ardea Biosciences Reports Recent Accomplishments and Announces ... - Earthtimes (press release) (press release)

Ardea Biosciences Reports Recent Accomplishments and Announces ... Earthtimes (press release) (press release) RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. ... Ardea Biosciences 2Q loss narrows on Bayer paymentCNBC all 12 news articles »